The network pharmacology and molecular docking analyses predicted that HCS inhibits the growth of and progression of BRCA by inactivating the PI3K-Akt/mTOR signaling pathway, which is known to regulate the proliferation, apoptosis, and migration of tumor cells. This evidence concerns the gene MTOR and neoplasm.